In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and ...
SAN ANTONIO, March 17, 2026--bioAffinity Technologies' new patient case study demonstrates the benefit of CyPath Lung in ...
The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...
Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...
InvestorsHub on MSN
BioAffinity launches large-scale clinical study for lung cancer detection technology
Affinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung technology ...
Understand and comply with relevant codes and standards such as NFPA 70B, NFPA 79, and NEC 110.7 to ensure proper insulation testing procedures. Develop a comprehensive job safety plan that includes ...
Background Treatment failure remains a major challenge in tuberculosis (TB) management. Rapid and objective assessment of treatment response is essential, as existing tools have limited accuracy and ...
New Jersey Medicare patients will be guinea pigs in a grand experiment that tests the capabilities of using artificial intelligence to decide which medical procedures should be covered by insurance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results